IAMA Therapeutics Appoints Federico Bolognani as Chief Medical Officer

GENOA, Italy, April 11, 2024 — IAMA Therapeutics today announced the appointment of Federico Bolognani, MD, PhD, as Chief Medical Officer (CMO). Bringing extensive expertise in clinical development and translational medicine, Dr. Bolognani joins the IAMA team to lead the advancement of therapeutic solutions for patients affected by neurodevelopmental disorders, epilepsy, and cognitive impairments.

Ciro Spedaliere, CEO of IAMA Therapeutics, commented: “We are thrilled to welcome Dr. Bolognani to our team. His proven track record in clinical research and strategic leadership will be invaluable as we continue to progress our lead compound, IAMA-6, through clinical development. With Dr. Bolognani as head of our medical team, we are confident in our ability to bring innovative treatments to patients in need.”

In response to his appointment, Dr. Federico Bolognani added: “I am honored to join IAMA Therapeutics and contribute to the advancement of novel therapies for CNS disorders. The potential of IAMA-6 to address critical unmet needs in neurology is remarkable, and I look forward to working closely with the team to bring this promising compound to patients.”

Dr. Federico Bolognani is a Physician Scientist with more than 15 years of experience in Drug Development. He has recently focused on the Biotechnology sector developing drugs for Neuroscience and Rare disorders (Therachon, Axial Therapeutics, VectivBio). In these companies, as the Head of Clinical Development, he led clinical programs that successfully delivered clinical trial results, culminating in the acquisition of two of them by larger pharmaceutical companies. He is also a member of the Scientific Board of diverse Patient Advocacy groups and Foundations in Neurodevelopmental disorders. Previously, he worked in the pharmaceutical industry at the Novartis Institutes of Biomedical Research (NIBR) and the Neuroscience and Rare Disease division at Roche, where he led different Clinical Drug Development programs with an emphasis in neurodevelopmental disorders, including Autism Spectrum Disorder. He performed his studies at the Medical School of the National University of La Plata in Argentina where he obtained his MD and PhD degrees.

About IAMA Therapeutics

IAMA Therapeutics is at the forefront of neuroscience drug discovery, dedicated to advancing therapeutic solutions for individuals with neurologic conditions.

The company’s compounds are small molecules targeting cation-chloride cotransporters, playing a key role in the pathology of CNS disorders. IAMA-6, the lead compound, is currently being tested in a First-in-Human Phase 1 clinical trial (NCT06300398).

For more information, please visit https://iamatherapeutics.com/

Contact

Ciro Spedaliere

media@iamatherapeutics.com